ARCT
Arcturus Therapeutics Holdings Inc. NASDAQ Listed May 22, 2013$7.23
Mkt Cap $198.0M
52w Low $5.90
7.7% of range
52w High $23.16
50d MA $7.96
200d MA $9.72
P/E (TTM)
-2.5x
EV/EBITDA
—
P/B
0.9x
Debt/Equity
0.1x
ROE
-30.7%
P/FCF
-2.7x
RSI (14)
41.50
ATR (14)
$0.44
Beta
2.44
50d MA
$7.96
200d MA
$9.72
Avg Volume
430.2K
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
10628 Science Center Drive · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -1.03 | -0.95 | +7.9% | 8.90 | -7.6% | +3.6% | -6.3% | -4.5% | +0.1% | -5.2% | — |
| Mar 3, 2026 | AMC | -0.92 | -1.03 | -12.0% | 7.91 | -5.1% | -4.2% | -4.4% | -1.9% | +3.5% | +3.5% | — |
| Nov 10, 2025 | AMC | -0.80 | -0.49 | +38.7% | 8.78 | +0.8% | -1.3% | -6.2% | -4.4% | -6.4% | -7.0% | — |
| Aug 11, 2025 | AMC | -1.11 | -0.34 | +69.4% | 11.39 | +7.3% | +30.7% | +29.0% | +0.1% | +1.3% | -8.1% | — |
| May 12, 2025 | AMC | -1.58 | -0.52 | +67.1% | 11.59 | +10.4% | +2.3% | -8.6% | +7.4% | +0.1% | +2.9% | — |
| Mar 6, 2025 | AMC | -0.33 | -1.11 | -236.4% | 15.97 | -7.3% | -8.9% | -1.8% | -7.6% | +7.9% | -2.5% | — |
| Nov 7, 2024 | AMC | -0.70 | -0.26 | +62.9% | 18.74 | +4.1% | +4.7% | +3.8% | -3.9% | -2.0% | -4.4% | — |
| Aug 5, 2024 | AMC | -1.85 | -0.64 | +65.4% | 19.79 | +12.8% | +0.2% | -5.5% | +0.3% | -3.8% | +4.8% | — |
| May 8, 2024 | AMC | -1.17 | -1.00 | +14.5% | 27.21 | +6.9% | -1.5% | +1.8% | +5.4% | +3.6% | -2.4% | — |
| Mar 7, 2024 | AMC | -1.69 | -0.32 | +81.1% | 37.19 | -3.2% | -0.9% | +2.8% | +2.1% | -2.0% | -4.0% | — |
| Nov 14, 2023 | AMC | -1.79 | -0.61 | +65.9% | 19.40 | +18.5% | +16.1% | -1.5% | +12.7% | -2.4% | -5.9% | — |
| Aug 7, 2023 | AMC | 0.09 | -1.98 | -2300.0% | 31.85 | -11.2% | -19.2% | +10.5% | +3.1% | -5.2% | +6.4% | — |
| May 9, 2023 | AMC | 2.92 | 0.88 | -69.9% | 28.95 | +3.5% | +1.6% | +10.0% | -5.5% | +0.2% | -7.1% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18 | B. Riley Securities | Upgrade | Neutral → Buy | — | $6.39 | $6.56 | +2.7% | +2.5% | +2.6% | -1.3% | +3.6% | -3.2% |
| Mar 5 | Citigroup | Maintains | Buy → Buy | — | $7.58 | $7.40 | -2.4% | -4.4% | -1.9% | +3.5% | +3.5% | -2.1% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.91 | $7.51 | -5.1% | -4.2% | -4.4% | -1.9% | +3.5% | +3.5% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $7.91 | $7.51 | -5.1% | -4.2% | -4.4% | -1.9% | +3.5% | +3.5% |
| Jan 6 | Citigroup | Maintains | Neutral → Neutral | — | $6.37 | $6.26 | -1.7% | +3.8% | +3.5% | -1.0% | +0.1% | +11.1% |
| Nov 13 | Citigroup | Maintains | Neutral → Neutral | — | $8.13 | $8.03 | -1.2% | -4.4% | -6.4% | -7.0% | -2.1% | -8.8% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.78 | $8.85 | +0.8% | -1.3% | -6.2% | -4.4% | -6.4% | -7.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $8.78 | $8.85 | +0.8% | -1.3% | -6.2% | -4.4% | -6.4% | -7.0% |
| Oct 24 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $12.00 | $12.00 | +0.0% | -6.5% | -5.6% | -6.7% | -4.5% | +2.0% |
| Oct 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.54 | $11.42 | -1.0% | +4.0% | -6.5% | -5.6% | -6.7% | -4.5% |
| Oct 23 | Guggenheim | Downgrade | Buy → Neutral | — | $11.54 | $11.42 | -1.0% | +4.0% | -6.5% | -5.6% | -6.7% | -4.5% |
| Oct 23 | Citigroup | Downgrade | Buy → Neutral | — | $11.54 | $11.42 | -1.0% | +4.0% | -6.5% | -5.6% | -6.7% | -4.5% |
| Oct 22 | BTIG | Maintains | Buy → Buy | — | $23.16 | $9.90 | -57.3% | -50.2% | +4.0% | -6.5% | -5.6% | -6.7% |
| Oct 22 | Guggenheim | Downgrade | Buy → Neutral | — | $23.16 | $9.90 | -57.3% | -50.2% | +4.0% | -6.5% | -5.6% | -6.7% |
| Aug 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $17.48 | $17.53 | +0.3% | +5.9% | -4.3% | -1.0% | -1.4% | +0.1% |
| Aug 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.39 | $12.22 | +7.3% | +30.7% | +29.0% | +0.1% | +1.3% | -8.1% |
| Aug 12 | Citigroup | Maintains | Buy → Buy | — | $11.39 | $12.22 | +7.3% | +30.7% | +29.0% | +0.1% | +1.3% | -8.1% |
| Jul 2 | Scotiabank | Maintains | Sector Outperform → Sector Outperform | — | $12.99 | $13.03 | +0.3% | +4.8% | +1.2% | -3.0% | +3.3% | +7.2% |
| May 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $11.86 | $11.66 | -1.7% | -8.6% | +7.4% | +0.1% | +2.9% | +5.9% |
| May 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.59 | $12.79 | +10.4% | +2.3% | -8.6% | +7.4% | +0.1% | +2.9% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.82 | $9.50 | -3.3% | -4.8% | +3.7% | +4.9% | +3.8% | -2.6% |
| Mar 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $14.55 | $14.35 | -1.4% | -1.8% | -7.6% | +7.9% | -2.5% | +1.3% |
| Mar 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.97 | $14.80 | -7.3% | -8.9% | -1.8% | -7.6% | +7.9% | -2.5% |
| Mar 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.97 | $14.80 | -7.3% | -8.9% | -1.8% | -7.6% | +7.9% | -2.5% |
| Mar 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $15.97 | $14.80 | -7.3% | -8.9% | -1.8% | -7.6% | +7.9% | -2.5% |
| Mar 6 | Leerink Partners | Maintains | Outperform → Outperform | — | $16.05 | $15.79 | -1.6% | -0.5% | -8.9% | -1.8% | -7.6% | +7.9% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.05 | $18.56 | +2.8% | -1.9% | -2.2% | -2.3% | +5.0% | -6.1% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.41 | $16.50 | +0.5% | +10.0% | -1.9% | -2.2% | -2.3% | +5.0% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.98 | $17.73 | -1.4% | -3.7% | -4.2% | +1.0% | +1.5% | -1.3% |
| Jan 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.07 | $19.28 | +1.1% | +9.2% | -9.0% | -5.1% | -3.7% | -4.2% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.24 | $16.85 | +3.8% | -3.1% | -5.8% | +0.1% | +4.3% | +6.7% |
| Dec 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.21 | $17.17 | -0.2% | -5.6% | -3.1% | -5.8% | +0.1% | +4.3% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.74 | $19.50 | +4.1% | +4.7% | +3.8% | -3.9% | -2.0% | -4.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.73 | $18.96 | +1.2% | +0.3% | -3.8% | +4.8% | +3.8% | -2.3% |
| Jul 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $23.66 | $23.84 | +0.8% | -9.2% | +2.1% | -2.2% | +0.6% | +4.2% |
| May 10 | Canaccord Genuity | Maintains | Buy → Buy | — | $26.79 | $26.90 | +0.4% | +1.8% | +5.4% | +3.6% | -2.4% | +5.1% |
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.76 | $33.33 | -1.3% | -1.8% | -0.1% | +2.3% | +2.6% | -7.6% |
| Mar 11 | Canaccord Genuity | Maintains | Buy → Buy | — | $36.86 | $37.82 | +2.6% | +2.8% | +2.1% | -2.0% | -4.0% | -0.2% |
| Mar 8 | Wells Fargo | Maintains | Overweight → Overweight | — | $37.19 | $35.99 | -3.2% | -0.9% | +2.8% | +2.1% | -2.0% | -4.0% |
| Mar 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.19 | $35.99 | -3.2% | -0.9% | +2.8% | +2.1% | -2.0% | -4.0% |
| Feb 8 | Citigroup | Maintains | Buy → Buy | — | $37.30 | $37.93 | +1.7% | +1.6% | +4.6% | +5.0% | -6.8% | -0.8% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.80 | $25.76 | -0.2% | -1.1% | -5.0% | -1.2% | +3.9% | -3.5% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.40 | $22.98 | +18.5% | +16.1% | -1.5% | +12.7% | -2.4% | -5.9% |
| Sep 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $26.73 | $26.93 | +0.7% | +1.8% | -6.5% | +0.4% | +0.4% | -4.6% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.87 | $28.14 | +1.0% | -4.9% | +1.5% | +1.2% | -3.6% | +1.8% |
| Sep 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.74 | $32.00 | +0.8% | -2.2% | +3.3% | -3.4% | +1.8% | -0.1% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $31.14 | $31.29 | +0.5% | +4.7% | +0.2% | -5.6% | +1.8% | +0.4% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.54 | $29.30 | -0.8% | +1.4% | -5.9% | -0.5% | +5.5% | +5.3% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.85 | $28.27 | -11.2% | -19.2% | +10.5% | +3.1% | -5.2% | +6.4% |
| Jul 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $30.81 | $31.70 | +2.9% | +15.0% | +3.4% | +1.9% | -5.0% | -3.7% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Ark Investment Management Llc | 2,769,518 | $21M | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 1,107,020 | $9M | New | Mar 2026 |
| 3 | Two Sigma Investments, Lp | 1,081,784 | $8M | Added | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 977,922 | $8M | New | Mar 2026 |
| 5 | Millennium Management | 478,557 | $4M | Added | Mar 2026 |
| 6 | Ubs Group Ag | 458,277 | $4M | Added | Mar 2026 |
| 7 | Morgan Stanley | 426,784 | $3M | Reduced | Dec 2025 |
| 8 | Jane Street Group, Llc | 422,419 | $3M | Added | Dec 2025 |
| 9 | Acadian Asset Management Llc | 280,500 | $2M | Reduced | Mar 2026 |
| 10 | D.e. Shaw & Co | 252,034 | $2M | Added | Mar 2026 |
| 11 | Northern Trust Corp | 219,613 | $2M | Added | Mar 2026 |
| 12 | Susquehanna International Group, Llp | 204,014 | $2M | Added | Mar 2026 |
| 13 | Bnp Paribas Financial Markets | 194,860 | $2M | Added | Mar 2026 |
| 14 | Renaissance Technologies Llc | 178,300 | $1M | Added | Mar 2026 |
| 15 | Jpmorgan Chase & Co | 197,815 | $1M | Reduced | Mar 2026 |
| 16 | Aqr Capital Management Llc | 161,278 | $1M | Added | Mar 2026 |
| 17 | Invesco Ltd. | 113,570 | $877K | Added | Mar 2026 |
| 18 | Bank Of New York Mellon Corp | 74,997 | $579K | Reduced | Mar 2026 |
| 19 | Iq Eq Fund Management (Ireland) Ltd | 91,576 | $561K | Added | Dec 2025 |
| 20 | Quantinno Capital Management Lp | 71,353 | $551K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$198.0M
Enterprise Value
-$32.9M
P/E (TTM)
-2.55x
Forward P/E
—
PEG Ratio
0.13x
P/B
0.93x
P/S
4.37x
P/FCF
-2.67x
EV/EBITDA
—
Shares Out
27.4M
Financials (TTM)
Revenue
$45.4M
Net Income
-$78.7M
EBITDA
-$67.5M
Free Cash Flow
-$74.3M
Op Cash Flow
-$74.3M
EPS Basic
$-2.40
EPS Diluted
$-2.83
EPS Forward
$-4.04
Gross Margin
91.2%
Op Margin
-196.7%
Net Margin
-173.5%
Balance Sheet
Total Assets
$271.1M
Total Liab.
$57.2M
Total Equity
$214.0M
Cash
$230.9M
LT Debt
$0
Book Value/Sh
$7.81
Debt/Equity
0.12x
Current Ratio
6.64
Quick Ratio
6.64
Returns & Growth
ROE
-30.7%
ROA
-24.3%
ROIC
-31.4%
Rev Growth YoY
-51.4%
EPS Growth YoY
+20.0%
Price Returns
2W
+1.1%
1M
-8.1%
3M
-3.8%
6M
+16.6%
12M
-36.8%
Technicals
52W High
$23.16
52W Low
$5.90
50d MA
$7.96
200d MA
$9.72
RSI (14)
41.50
ATR (14)
$0.44
Beta
2.44
Avg Volume
430K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$22.50
High
$25.00
Low
$20.00
Median
$22.50
Data updated apr 24, 2026 6:47pm
· Source: financialmodelingprep.com